Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04876456 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
A Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, sponsored by Jennifer King.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04876456 is a Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor that is active but no longer recruiting, run by Jennifer King. The registered enrollment target is 50 participants, below the 345-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04876456, a Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, is active but no longer recruiting, sponsored by Jennifer King.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for patients with incurable, refractory germ cell tumors. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.
Conditions Studied
Interventions
- DRUG Cabozantinib
Study Locations (1)
Indiana
- Indiana University Melvin & Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04876456
The ClinicalTrials.gov registry entry for NCT04876456 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 345-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (86% lower). The listed sponsor is Jennifer King, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib is the first listed.
NCT04876456 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT04876456 about?
NCT04876456 is a clinical study titled "A Phase II Trial of Cabozantinib With Patients With Refractory GCTs". The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for patients with incurable, refractory germ cell tumors. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for w...
What is the current status of trial NCT04876456?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-06-10. Estimated completion is 2027-01.
What conditions does trial NCT04876456 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Ovarian Germ Cell Tumor, Non-seminomatous Germ Cell Tumor, Seminoma.
What interventions are being tested in trial NCT04876456?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04876456?
This trial is sponsored by Jennifer King, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04876456 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
RECRUITING · Phase 2
-
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.